GET DAILY SIGNALSAlumis (ALMS): Analyst Targets Point to a $30 Level and +375% Upside
Key Takeaways
- The central target of $30 is the arithmetic mean of five analyst price targets that were updated after Alumis' September 2026 lupus trial setback, with a range of $25 to $44.
- With the stock near $6.30, reaching $30 would require roughly 375% upside — a very large move.
- Targets stay elevated because analysts value the psoriasis franchise (envudeucitinib), for which an FDA filing is expected in the fourth quarter of 2026.
- The shares trade near cash value after falling about 80% from their 52-week high of $31.35.
- The strongest supports are positive Phase 3 psoriasis data and a cash position of about $431 million; the biggest risks are single-asset concentration and financing needs.
- For more on this ticker's Major News, Today's Price Move, Forecast, and Earnings, explore Tickeron's dedicated pages.
Understanding the Analyst Consensus on ALMS
Alumis Inc. (ALMS) is a clinical-stage biopharmaceutical company developing oral TYK2 (tyrosine kinase 2) inhibitors for autoimmune diseases. Following a pivotal September 2026 event, a review of five updated analyst price targets produces an arithmetic mean of $30, with a low of $25 and a high of $44.
The individual post-event targets include Morgan Stanley at $29 (Overweight), Wells Fargo at $25 (Overweight, analyst Derek Archila), H.C. Wainwright at $25 (Neutral), Robert W. Baird at $27 (lowered from $35), and Stifel at $44 (Buy). Third-party aggregators have published wider consensus figures spanning roughly $31 to $33, with broader low-high bands, but those figures include pre-crash and less recently updated targets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The dispersion reflects genuine disagreement about how much of the failed lupus program to value. Wells Fargo cut its target from $51 to $25 after trimming the lupus probability of success, while Stifel retained a $44 view by focusing on the mechanism's potential in interferon-driven disease. This wide $25–$44 range signals high uncertainty rather than a clean consensus, and the $30 mean should not be read as a forecast or guarantee.
Where ALMS Stands Today and the Road Ahead
As of mid-November 2026, ALMS trades near $6.30, down about 80% from its 52-week high of $31.35 and not far above its 52-week low of $4.60. Reaching the $30 central target implies upside of roughly 375%, a very large move that would require the market to fully re-price the psoriasis opportunity.
The path would most plausibly run through execution on the lead program. Alumis' lead candidate, envudeucitinib, met endpoints in its Phase 3 ONWARD studies in moderate-to-severe plaque psoriasis, and management has guided to a new drug application (NDA) filing with the FDA in Q4 2026. A clean filing and eventual approval could begin to close the gap between the current price and the elevated analyst targets.
Factors That Could Drive the Stock Higher
- Phase 3 psoriasis data has been positive, with high skin-clearance rates (PASI 90 and PASI 100) that support a commercial case for an oral option in a category dominated by injectables.
- A cash position of about $431 million as of September 30, 2026, provides a runway the company estimates into Q4 2027, reducing near-term dilution risk.
- Insider buying and the persistence of bullish ratings suggest some investors still see meaningful franchise value above the current price.
- A successful FDA filing or approval catalyst could prompt upward analyst revisions and investor re-rating.
Risks That Might Keep Targets Out of Reach
- The Phase 2b LUMUS trial in systemic lupus erythematosus (SLE) missed its primary and secondary endpoints in the overall population, removing a major expansion opportunity near term.
- The company is essentially single-asset: with no approved products and minimal revenue, its valuation rests almost entirely on envudeucitinib's psoriasis launch.
- Ongoing net losses (roughly $95 million in Q3 2026) mean additional financing is likely, which could dilute shareholders.
- Commercialization in psoriasis is competitive, and Alumis has signaled it may pursue a partnership rather than launch alone, which could reduce per-share economics.
Technical Picture and Key Levels
The stock's 52-week high of $31.35 and low of $4.60 frame a dramatic, roughly 80% drawdown. Near-term support sits around the $4.60 low and the per-share cash value (approximately $3.76 based on September 2026 balances), which has helped cushion the decline. The post-crash bounce toward $10 represents a meaningful resistance area, while the analyst-target zone of $25 and above remains far above current trading and would require a fundamental re-rating rather than a technical recovery.
What to Watch Going Forward
Analyst price targets generally reflect a research horizon of around 12 months, though the actual horizon varies by firm and is not always disclosed. The most important upcoming items are the psoriasis NDA filing expected in Q4 2026, any FDA feedback on the lupus subgroup path forward, quarterly cash-burn and runway updates, financing announcements, and analyst target revisions. Economic conditions and interest rates matter less for this clinical-stage story than execution and regulatory outcomes. From what I see, monitoring these catalysts closely will be essential.
Exploring Tickeron’s AI Daily Buy/Sell Signals
In my own research process I often turn to Tickeron’s AI Daily Buy/Sell Signals to stay on top of fast-moving names like this one. The platform uses artificial intelligence to monitor thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. For a catalyst-driven stock such as ALMS, these signals can help surface opportunities and track trend changes more efficiently than manual review alone. I find it a useful complement when weighing the wide range of analyst views.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALMS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for ALMS moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 14 of the 14 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 22 of 31 cases where ALMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
Following a +11.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMS advanced for three days, in 100 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
ALMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALMS as a result. In 34 of 39 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for ALMS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.726) is normal, around the industry mean (3.498). P/E Ratio (-1.467) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (123.457) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. ALMS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology